Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SXQYA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
T-D265C-CN-Pro-amanitin
|
|||||
| Synonyms |
T-D265C CN-Pro-amanitin
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab D265C
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
CN-Pro-dideoxy-alpha-amanitin
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Mal-Val-Ala-PAB
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugated of maleimidocaproyl with two D265C free thiol in heavy chains, Michael addition reaction.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.